Filtered By:
Condition: Brain Tumor
Cancer: Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 5560 results found since Jan 2013.

Glioma Response to IDH Inhibition: Real-World Experience
Clin Cancer Res. 2023 Sep 22. doi: 10.1158/1078-0432.CCR-23-2164. Online ahead of print.ABSTRACTTreatment of IDH mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. IDH inhibition has a therapeutic benefit in patients with these tumors.PMID:37738033 | DOI:10.1158/1078-0432.CCR-23-2164
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Rimas V Lukas Craig Horbinski Source Type: research

A H3K27M-targeted vaccine in adults with diffuse midline glioma
Nat Med. 2023 Sep 21. doi: 10.1038/s41591-023-02555-6. Online ahead of print.ABSTRACTSubstitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide vaccine (H3K27M-vac) induces mutation-specific immune responses that control H3K27M+ tumors in major histocompatibility complex-humanized mice. Here we describe a first-in-human treatment with H3K27M-vac of eight adult patients with progressive H3K27M+ diffuse midline glioma on a compassionate use basis. Five patients received H3K27M-vac combined with anti-PD-1 treat...
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Niklas Grassl Isabel Poschke Katharina Lindner Lukas Bunse Iris Mildenberger Tamara Boschert Kristine J ähne Edward W Green Ingrid H ülsmeyer Simone J ünger Tobias Kessler Abigail K Suwala Philipp Eisele Michael O Breckwoldt Peter Vajkoczy Oliver M Gra Source Type: research

Single-cell and bulk sequencing analyses reveal the immune suppressive role of PTPN6 in glioblastoma
Aging (Albany NY). 2023 Sep 21;15. doi: 10.18632/aging.205052. Online ahead of print.ABSTRACTGlioblastoma (GBM) is a highly malignant brain cancer with a poor prognosis despite standard treatments. This investigation aimed to explore the feasibility of PTPN6 to combat GBM with immunotherapy. Our study employed a comprehensive analysis of publicly available datasets and functional experiments to assess PTPN6 gene expression, prognostic value, and related immune characteristics in glioma. We evaluated the influence of PTPN6 expression on CD8+ T cell exhaustion, immune suppression, and tumor growth in human GBM samples and mo...
Source: Aging - September 22, 2023 Category: Biomedical Science Authors: Xiaonan Zhang Jie Chen Ming Zhang Saisai Liu Tao Wang Tianyu Wu Baiqing Li Shidi Zhao Hongtao Wang Li Li Chun Wang Li Huang Source Type: research

Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies
CONCLUSIONS: In this study we report that an inherent enrichment of distinct GSCs pools underpin the functional inter-cluster variances displayed by GBM patients. We uncover two selectively represented novel functional biomarkers capable of discriminating GBM patients' stratification, survival and drug response, setting the stage for the determination of patient-tailored diagnostic and prognostic strategies and, mostly, for the design of appropriate, patient-selective treatment protocols.PMID:37735434 | DOI:10.1186/s13046-023-02811-0
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Alberto Visioli Nadia Trivieri Gandino Mencarelli Fabrizio Giani Massimiliano Copetti Orazio Palumbo Riccardo Pracella Maria Grazia Cariglia Chiara Barile Luigi Mischitelli Amata Amy Soriano Pietro Palumbo Federico Legnani Francesco DiMeco Leonardo Gorgog Source Type: research

Cancers, Vol. 15, Pages 4686: The Role of the Dysregulation of Long Non-Coding and Circular RNA Expression in Medulloblastoma: A Systematic Review
ldaiturriaga Medulloblastoma (MB) is the most common malignant brain tumor in childhood. Although recent multi-omic studies have led to advances in MB classification, there is still room for improvement with regard to treatment response and survival. Therefore, identification of new and less invasive biomarkers is needed to refine the diagnostic process and to develop more personalized treatment strategies. In this context, non-coding RNAs (ncRNAs) could be useful biomarkers for MB. In this article, we reviewed the role of two types of ncRNAs, long non-coding (lncRNAs) and circular RNAs (circRNAs), as biomarkers for th...
Source: Cancers - September 22, 2023 Category: Cancer & Oncology Authors: Ivan Martinez de Estibariz Anastasija Jakjimovska Unai Illarregi Idoia Martin-Guerrero Angela Guti érrez-Camino Elixabet Lopez-Lopez Nerea Bilbao-Aldaiturriaga Tags: Systematic Review Source Type: research

< em > PLEKHA4 < /em > is Associated with Tumour Microenvironment, Stemness, Proliferation and Poor Prognosis of Gliomas
CONCLUSIONS: PLEKHA4 is highly expressed in glioma tissues and correlated with tumour stemness, immune cell infiltration and proliferation, suggesting its potential as a novel prognostic biomarker and therapeutic target in glioma.PMID:37735118 | DOI:10.31083/j.jin2205130
Source: Journal of Integrative Neuroscience - September 21, 2023 Category: Neuroscience Authors: Xin Gao Yukun Liu Shunming Hong Hui Yang Bing Guan Xiaodong Ma Source Type: research

Proteomic landscape of primary and metastatic brain tumors for heterogeneity discovery
CONCLUSIONS AND CLINICAL RELEVANCE: We characterized an extensive proteomic landscape of BrMs and gliomas. These findings have promising implications for the development of targeted therapies for BrMs and gliomas.PMID:37726528 | DOI:10.1002/prca.202300010
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Shuang Yang Chengbin Zhou Lei Zhang Yueting Xiong Yongtao Zheng Liuguan Bian Xiaohui Liu Source Type: research

Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence
CONCLUSIONS: This work suggests a potential benefit for combining senolytics with immunotherapy in older patients with GBM.PMID:37725593 | DOI:10.1158/1078-0432.CCR-23-0834
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Margaret Johnson April Bell Kristen L Lauing Erik Ladomersky Lijie Zhai Manon Penco-Campillo Yajas Shah Elizabeth Mauer Joanne Xiu Theodore Nicolaides Michael Drumm Kathleen McCortney Olivier Elemento Miri Kim Prashant Bommi Justin T Low Ruba Memon Jennif Source Type: research

Proteomic landscape of primary and metastatic brain tumors for heterogeneity discovery
CONCLUSIONS AND CLINICAL RELEVANCE: We characterized an extensive proteomic landscape of BrMs and gliomas. These findings have promising implications for the development of targeted therapies for BrMs and gliomas.PMID:37726528 | DOI:10.1002/prca.202300010
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Shuang Yang Chengbin Zhou Lei Zhang Yueting Xiong Yongtao Zheng Liuguan Bian Xiaohui Liu Source Type: research